Dafna Capital Management LLC 89bio, Inc. Transaction History

Dafna Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.52 - $12.73 $1.83 Million - $4.21 Million	-330,689 Reduced 50.5%	324,173 $4.13 Million
Q3 2022 Nov 14, 2022	SELL	$3.02 - $7.0 $337,974 - $783,384	-111,912 Reduced 14.6%	654,862 $3.79 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $925,286 - $1.78 Million	442,721 Added 136.62%	766,774 $2.47 Million
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $618,930 - $2.69 Million	179,400 Added 124.02%	324,053 $1.22 Million
Q4 2021 Feb 14, 2022	BUY	$11.15 - $19.66 $200,711 - $353,899	18,001 Added 14.21%	144,653 $1.89 Million
Q3 2021 Nov 15, 2021	BUY	$14.91 - $21.31 $152,082 - $217,362	10,200 Added 8.76%	126,652 $2.48 Million
Q2 2021 Aug 16, 2021	BUY	$17.42 - $28.0 $191,167 - $307,272	10,974 Added 10.4%	116,452 $2.18 Million
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $115,800 - $140,400	-5,000 Reduced 4.53%	105,478 $2.57 Million
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $2.19 Million - $3.49 Million	90,000 Added 439.5%	110,478 $2.84 Million
Q2 2020 Aug 14, 2020	BUY	$19.93 - $31.2 $408,126 - $638,913	20,478 New	20,478 $408,000

175

125M

84K

941K

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $491M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.